Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Overhaul Your Rest: Tips for a Serene Evening - 2Doomed SpaceX Starlink satellite photographed from orbit
- 3Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- 4Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- 5‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- Mussolini's summer villa on Adriatic coast sold for €1.2 million
- Florida has quietly become America's execution capital
- Astronauts beam home Christmas wishes from International Space Station: 'I think we may be orbiting a little higher than Santa' (video)
- Picking the Right Home Machines: A Commonsense Aide
- Beyond oil: The crucial exports blocked by Hormuz closure
- Oil, energy and food: Which countries in Europe are most exposed to higher food prices?
- Find the Specialty of Public Speaking: Drawing in and Convincing Crowds with Certainty
- FDA proposes use of sunscreen ingredient popular in other countries
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
